Combined B cell/T cell therapy as novel approach for the re-induction of humoral immune-tolerance.

B 细胞/T 细胞联合疗法作为重新诱导体液免疫耐受的新方法。

• 批准号: 418296028
• 负责人: Professor Dr. Gerhard Krönke, since 1/2019
• 金额: --
• 依托单位: Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie (einschließlich Arbeitsbereich Physikalische Medizin)
• 依托单位国家: 德国
• 项目类别: Research Units
• 财政年份: 2019
• 资助国家: 德国
• 起止时间: 2018-12-31 至 2023-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/418296028?language=en
• 关键词: Combined; cell; therapy; novel; approach

Despite considerable efforts and success in the development of anti-inflammatory drugs, there is yet no curative treatment for rheumatoid arthritis (RA). In the proposed investigator initiated trial we aim to sequentially combine a B cell-targeted therapy and a T cell-targeted therapy to induce a state of clinical remission as well as to re-establish immune tolerance in autoantibody-positive RA patients. ACPA-positive active RA patients will receive rituximab, followed by a treatment with abatacept or placebo. Primary outcome is the change in autoantibody (ACPA) levels, while secondary outcomes will be the change ACPA glycosylation and in B cell and T cell responses as well as the effects on clinical disease activity.

尽管在抗炎药物的开发方面付出了巨大的努力并取得了成功，但类风湿性关节炎（RA）仍然没有有效的治疗方法。在拟议的研究者发起的试验中，我们的目标是依次结合 B 细胞靶向治疗和 T 细胞靶向治疗，以诱导自身抗体阳性 RA 患者临床缓解状态并重新建立免疫耐受。 ACPA 阳性活动性 RA 患者将接受利妥昔单抗治疗，然后接受阿巴西普或安慰剂治疗。主要结果是自身抗体 (ACPA) 水平的变化，而次要结果是 ACPA 糖基化、B 细胞和 T 细胞反应的变化以及对临床疾病活动的影响。